Genolution

Genolution Debt / Assets

The Debt-to-Assets Ratio of Genolution (225220.KQ) as of Nov 19, 2026 is 0.23. In the previous year, Debt-to-Assets Ratio was 0.21 — a change of 6.57% (higher).

Debt / Assets

0.23

YoY

6.57%

Last updated:

Debt-to-Assets Ratio of Genolution is 2024 0.23 . Debt-to-Assets Ratio of Genolution was 2023 0.21 . It decreases by 6.57% higher compared to the previous year.

The Genolution Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2017
0.00 KRW
Jan 1, 2018
0.15 KRW
Jan 1, 2019
0.26 KRW
Jan 1, 2020
0.08 KRW
Jan 1, 2021
0.00 KRW
Jan 1, 2022
0.13 KRW
Jan 1, 2023
0.21 KRW
Jan 1, 2024
0.23 KRW
The Genolution Debt / Assets history
YEARDebt / AssetsYoY
0.23+6.57%
0.21+61.28%
0.13—
0.00-100.00%
0.08-70.00%
0.26+78.65%
0.15—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Debt-to-Assets Ratio of Genolution is 0.23 in 2024.

Debt-to-Assets Ratio of Genolution changed from 0.21 to 0.23, representing a 6.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Genolution since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Genolution with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genolution

All Key Metrics — Genolution